Pharming Group

Pharming Group CROIC

The Cash Return on Invested Capital (CROIC) of Pharming Group (PHARM.AS) as of Nov 19, 2026 is 13.03 %. In the previous year, Cash Return on Invested Capital (CROIC) was -0.79 % — a change of -1,743.06% (higher).

CROIC

13.03 %

YoY

-1,743.06%

Last updated:

Cash Return on Invested Capital (CROIC) of Pharming Group is 2025 13.03 % . Cash Return on Invested Capital (CROIC) of Pharming Group was 2024 -0.79 % . It decreases by -1,743.06% higher compared to the previous year.

The Pharming Group CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2018
27.18 USD
Jan 1, 2019
28.00 USD
Jan 1, 2020
21.54 USD
Jan 1, 2021
5.69 USD
Jan 1, 2022
5.63 USD
Jan 1, 2023
-5.92 USD
Jan 1, 2024
-0.79 USD
Jan 1, 2025
13.03 USD
The Pharming Group CROIC history
YEARCROICYoY
13.03 %-1,743.06%
-0.79 %-86.60%
-5.92 %-204.99%
5.63 %-1.03%
5.69 %-73.57%
21.54 %-23.08%
28.00 %+3.02%
27.18 %-15.42%
32.14 %-364.66%
-12.14 %-72.17%
-43.62 %+152.39%
-17.28 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pharming Group Stock analysis

What does Pharming Group do? Pharming Group NV was founded in 1988 and is headquartered in the Netherlands. The company specializes in the development and marketing of medical products for the treatment of rare diseases. Its business model is based on the discovery and development of recombinant proteins. These proteins are produced using genetic engineering techniques and serve as the foundation for the development of therapeutic products in various areas. The main focus of Pharming Group NV is the manufacturing and marketing of biopharmaceuticals. The company has a wide range of products used in the treatment of rare diseases, including C1-esterase inhibitor preparations used for acute attacks in hereditary angioedema. Another important product of Pharming Group NV is recombinant human lysozyme. It is used in the treatment of cystic fibrosis and has shown promising results as a therapeutic approach. Pharming Group NV also collaborates closely with various research and development organizations to develop new products and expand knowledge in the medical industry. The company has experienced impressive growth in recent years. In 2019, Pharming Group NV achieved a revenue of 149 million euros. A significant portion of this revenue was generated through the sale of C1-esterase inhibitor preparations. Pharming Group NV has also made a name for itself in the international market. The company has branches in the USA and Europe and works closely with international regulatory authorities to ensure smooth approval and marketing of its products. Overall, Pharming Group NV has a promising future as it continues to invest in research, development, and expansion of its product portfolio. By focusing on the development of products for the treatment of rare diseases, Pharming Group NV positions itself as a leading company in the medical industry and contributes to improving the lives of people worldwide. Pharming Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pharming Group stock

Cash Return on Invested Capital (CROIC) of Pharming Group is 13.03 % in 2025.

Cash Return on Invested Capital (CROIC) of Pharming Group changed from -0.79 % to 13.03 %, representing a -1,743.06% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Pharming Group since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Pharming Group with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Pharming Group

All Key Metrics — Pharming Group